(IN BRIEF) Bayer has invested $250 million in a new cell therapy production plant in Berkeley, California, USA. This investment aims to support the production of materials for clinical trials and potential commercial launches of BlueRock Therapeutics’ bemdaneprocel (BRT-DA01), an … Read the full press release →
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science
Tagged Bayer, Bemdaneprocel, Berkeley, BRT-DA01, California, Cell Therapy Plant, Holger Weintritt, Parkinson's disease, partnership, Seth Ettenberg, Stefan Oelrich, sustainability, USA